نتایج جستجو برای: ras mutations

تعداد نتایج: 198454  

Journal: :Carcinogenesis 2005
Sandra Bloethner Bowang Chen Kari Hemminki Jan Müller-Berghaus Selma Ugurel Dirk Schadendorf Rajiv Kumar

We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene-four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts. Data analysis using stringent criteria revealed several upregulated and downregulated genes in cell lines...

Journal: :Cancer Treatment Reviews 2021

The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular processes such as gene expression, cell proliferation, survival, and apoptosis. Also known the RAS-RAF-MEK-ERK pathway, MAPK has been implicated approximately one-third of all cancers. Mutations RAS or RAF genes KRAS BRAF are common, these mutations typically promote malignancies by over-activating MEK ERK downst...

Journal: :Clinical chemistry 2005
Sonya Trombino Monica Neri Riccardo Puntoni Cristiano Angelini Maura Loprevite Alfredo Cesario Pierluigi Granone Andrea Imperatori Lorenzo Dominioni Andrea Ardizzoni Rosangela Filiberti Patrizia Russo

To the Editor: The demonstration that cell-free circulating DNA detected in the plasma of cancer patients is genetically identical to that of the primary tumor has generated substantial interest, leading to 200 publications (http:// www.ncbi.nlm.nih.gov). Recently, Wang et al. (1 ) reported in this journal that the method chosen for DNA isolation might contribute significantly to mutation detec...

2015
Mariana Petaccia de Macedo Fernanda Machado de Melo Júlia da Silva Ribeiro Celso Abdon Lopes de Mello Maria Dirlei Ferreira de Souza Begnami Fernando Augusto Soares Dirce Maria Carraro Isabela Werneck da Cunha

INTRODUCTION Mutations in KRAS and NRAS genes are negative predictors of anti-EGFR therapies response in metastatic colorectal cancer. There are few reports on RAS testing in synchronous primary colorectal cancer (SP-CRC) and a lack of recommendations on which tissue should be tested for the mutation in this disease. This study analyzed the RAS status of both lesions in SP-CRC patients and in t...

Journal: :Cancer research 1988
S Rodenhuis R J Slebos A J Boot S G Evers W J Mooi S S Wagenaar P C van Bodegom J L Bos

47 tumor samples, 45 of which were obtained at thoracotomy for non-small cell lung cancer were examined for mutational activation of the oncogenes H-ras, K-ras, and N-ras. A novel, highly sensitive assay based on oligonucleotide hybridization following an in vitro amplification step was employed. ras gene mutations were present in nine of 35 adenocarcinomas of the lung (all K-ras), in two of tw...

Journal: :Cancer research 2010
Manickam Janakiraman Efsevia Vakiani Zhaoshi Zeng Christine A Pratilas Barry S Taylor Dhananjay Chitale Ensar Halilovic Manda Wilson Kety Huberman Julio Cezar Ricarte Filho Yogindra Persaud Douglas A Levine James A Fagin Suresh C Jhanwar John M Mariadason Alex Lash Marc Ladanyi Leonard B Saltz Adriana Heguy Philip B Paty David B Solit

Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently been adopted. We performed a multiplatform genomic analysis to characterize, in a nonbiased manner, the biological, biochemical, a...

Journal: :Cancer research 1999
C C Schimanski U Linnemann M R Berger

Postoperative survival of colorectal cancer patients is often delineated by metastases spreading to the liver. Current clinical diagnostic procedures are unable to discover micrometastases in this organ. Our aim was to develop a diagnostic tool for detecting micrometastases that are present at the time of surgery. Therefore, a PCR-RFLP assay was set up tracking point mutations of the K-ras onco...

Journal: :Zhongguo fei ai za zhi = Chinese journal of lung cancer 2010
Yang Zhang Zhenkui Pan Xing Zhang Fei Xu Li Zhang

BACKGROUND AND OBJECTIVE Recent studies indicated that Non-small cell lung cancer (NSCLC) patients with mutant K-RAS failed to benefit from adjuvant chemotherapy, and the cancer did not respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). These findings indicated that K-RAS gene status can be a biomarker to predict the sensitivity of EGFR TKIs. The aim of this s...

Journal: :Blood 2009
Mignon L Loh Debbie S Sakai Christian Flotho Michelle Kang Manfred Fliegauf Sophie Archambeault Charles G Mullighan Leslie Chen Eva Bergstraesser Carlos E Bueso-Ramos Peter D Emanuel Henrik Hasle Jean-Pierre Issa Marry M van den Heuvel-Eibrink Franco Locatelli Jan Stary Monica Trebo Marcin Wlodarski Marco Zecca Kevin M Shannon Charlotte M Niemeyer

Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, w...

2011
Vincent Runtuwene Mark van Eekelen John Overvoorde Holger Rehmann Helger G. Yntema Willy M. Nillesen Arie van Haeringen Ineke van der Burgt Boudewijn Burgering Jeroen den Hertog

Noonan syndrome is a relatively common developmental disorder that is characterized by reduced growth, wide-set eyes and congenital heart defects. Noonan syndrome is associated with dysregulation of the Ras-mitogen-activated-protein-kinase (MAPK) signaling pathway. Recently, two mutations in NRAS were reported to be associated with Noonan syndrome, T50I and G60E. Here, we report a mutation in N...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید